沃森生物子公司收到13价肺炎球菌多糖结合疫苗约旦药品注册证

Core Viewpoint - Watson Bio (300142.SZ) announced that its subsidiary, Yuxi Watson Biotechnology Co., Ltd., has received a drug registration certificate from the Jordan Food & Drug Administration for its 13-valent pneumococcal polysaccharide conjugate vaccine [1] Group 1: Product Information - The 13-valent pneumococcal polysaccharide conjugate vaccine is primarily intended for infants and children aged 6 weeks to under 5 years [1] - The vaccine is designed to prevent infections caused by 13 serotypes of pneumococcus included in the vaccine: types 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F [1] - This vaccine was approved for sale in China in 2020 [1]